Articles with public access mandates - Jack RothLearn more
OverallNIHNSFNSFCDFGEuropean CommissionDOESNSFNWOGovernment of SpainGovernment of ItalyCPRITCASSTFCANRNCNDoDFNRSUK Research & InnovationHelmholtzMRCBMBFFWOVAFRQSHRBSFIDSTCancer Research UKEPSRCNational Centre for the Replacement, Refinement and Reduction of Animals in Research, UKNIHRZonMwDoris Duke Charitable FoundationKWFLUNGevity Foundation, USAAIRC Foundation for Cancer Research in ItalyDamon Runyon Cancer Research FoundationCZI
Not available anywhere: 6
Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection
N Deboever, DJ McGrail, Y Lee, HT Tran, KG Mitchell, MB Antonoff, ...
Lung Cancer 164, 69-75, 2022
Mandates: US National Institutes of Health
Pulmonary resection for tissue harvest in adoptive tumor‐infiltrating lymphocyte therapy: Safety and feasibility
EM Corsini, KG Mitchell, N Zhou, C Bernatchez, MA Forget, CL Haymaker, ...
Journal of surgical oncology 124 (4), 699-703, 2021
Mandates: US National Institutes of Health
Multifunctional tumor-targeted nanoparticles for lung cancer
S Kuroda, T Yokoyama, JO Tam, AW Scott, LL Ma, M Shanker, J Jin, ...
Pulm Nanomed, 15-44, 2013
Mandates: US National Institutes of Health
SABR for operable stage I non-small-cell lung cancer: comparison to surgery–Authors' reply
JY Chang, V Verma, L Feng, JA Roth
The Lancet Oncology 22 (12), e537-e538, 2021
Mandates: US National Institutes of Health
Use of telomere length in peripheral leukocytes to predict risk of recurrence in patients with early-stage non-small cell lung cancer after curative resection.
ES Kim, AA Vaporciyan, J Xing, M Huang, MR Spitz, SM Lippman, J Gu, ...
Journal of Clinical Oncology 28 (15_suppl), 7031-7031, 2010
Mandates: US National Institutes of Health
Tumour‐Suppressor Gene Therapy
B Fang, JA Roth
Viral Therapy of Cancer, 229-239, 2008
Mandates: US National Institutes of Health
Available somewhere: 186
Somatic mutations affect key pathways in lung adenocarcinoma
L Ding, G Getz, DA Wheeler, ER Mardis, MD McLellan, K Cibulskis, ...
Nature 455 (7216), 1069-1075, 2008
Mandates: US National Institutes of Health
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
JY Chang, S Senan, MA Paul, RJ Mehran, AV Louie, P Balter, HJM Groen, ...
The lancet oncology 16 (6), 630-637, 2015
Mandates: US National Institutes of Health, Netherlands Organisation for Health …
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
CM Gay, CA Stewart, EM Park, L Diao, SM Groves, S Heeke, BY Nabet, ...
Cancer cell 39 (3), 346-360. e7, 2021
Mandates: US Department of Defense, US National Institutes of Health, LUNGevity …
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ...
Nature medicine 27 (3), 504-514, 2021
Mandates: US National Institutes of Health
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
X Le, S Puri, MV Negrao, MB Nilsson, J Robichaux, T Boyle, JK Hicks, ...
Clinical Cancer Research 24 (24), 6195-6203, 2018
Mandates: US National Institutes of Health
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy
A Pataer, N Kalhor, AM Correa, MG Raso, JJ Erasmus, ES Kim, ...
Journal of Thoracic Oncology 7 (5), 825-832, 2012
Mandates: US National Institutes of Health
Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA
R Huschka, A Barhoumi, Q Liu, JA Roth, L Ji, NJ Halas
ACS nano 6 (9), 7681-7691, 2012
Mandates: US National Institutes of Health
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
CA Stewart, CM Gay, Y Xi, S Sivajothi, V Sivakamasundari, J Fujimoto, ...
Nature cancer 1 (4), 423-436, 2020
Mandates: US Department of Defense, US National Institutes of Health
miR-93, miR-98, and miR-197 Regulate Expression of Tumor Suppressor Gene FUS1
L Du, JJ Schageman, MC Subauste, B Saber, SM Hammond, L Prudkin, ...
Molecular Cancer Research 7 (8), 1234-1243, 2009
Mandates: US National Institutes of Health
Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non–small-cell lung cancer
JY Chang, PA Balter, L Dong, Q Yang, Z Liao, M Jeter, MK Bucci, ...
International Journal of Radiation Oncology* Biology* Physics 72 (4), 967-971, 2008
Mandates: US National Institutes of Health
Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”
JY Chang, QQ Li, QY Xu, PK Allen, N Rebueno, DR Gomez, P Balter, ...
International Journal of Radiation Oncology* Biology* Physics 88 (5), 1120-1128, 2014
Mandates: US National Institutes of Health
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified …
JY Chang, RJ Mehran, L Feng, V Verma, Z Liao, JW Welsh, SH Lin, ...
The Lancet Oncology 22 (10), 1448-1457, 2021
Mandates: US National Institutes of Health
Angular Analysis of the Decay
R Aaij, CA Beteta, T Ackernley, B Adeva, M Adinolfi, H Afsharnia, ...
Physical Review Letters 126 (16), 161802, 2021
Mandates: US National Science Foundation, US Department of Energy, Swiss National …
Phase I clinical trial of systemically administered TUSC2 (FUS1)-nanoparticles mediating functional gene transfer in humans
C Lu, DJ Stewart, JJ Lee, L Ji, R Ramesh, G Jayachandran, MI Nunez, ...
PloS one 7 (4), e34833, 2012
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program